Mode
Text Size
Log in / Sign up
N/A N=134 Randomized Triple-blind Treatment

Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery

Analgesia, Obstetrical · Obstetric Surgical Procedures

Enrolled (actual)
134
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcome: Primary: NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration — 4; 3 score on a scale — p=0.132

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Morphine (Drug); Hydromorphone (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Mayo Clinic
Primary completion
Sep 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration
4; 3 0.132
SECONDARY
Nausea
28; 32 0.590
SECONDARY
Pruritus
27; 28 0.971

Summary

Intrathecal (IT) opioids are commonly administered with local anesthetic during spinal anesthesia for post-Cesarean delivery analgesia. Traditionally, IT morphine has been used but the use of IT hydromorphone is growing. A previous study has shown that the effective dose for postoperative analgesia in 90% patients (ED90) for both IT hydromorphone and IT morphine (NCT02009722). These doses were found to be 75 mcg for hydromorphone and 150 mcg for morphine. The current proposed study would compare the duration of analgesia of IT morphine vs IT hydromorphone after elective cesarean delivery. Additionally, the investigators will compare each drug with respect the incidence of nausea and pruritus.

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologists (ASA) physical status II-III women presenting for elective cesarean delivery
  • Term gestation (37-42 weeks)
  • Desire to have a spinal anesthesia technique for cesarean delivery

Exclusion Criteria

  • Any contraindication to the administration of a spinal technique for anesthesia
  • History of intolerance or adverse reaction to opioid medications
  • Chronic pain syndrome or current opioid use >30 oral morphine equivalents/day
  • Allergy or intolerance to acetaminophen, ketorolac, ibuprofen, or oxycodone
  • Current BMI > 50
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02789410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search